Methicillin resistant staphylococcus aureus screening

Methicillin resistant staphylococcus aureus infections Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Methicillin resistant staphylococcus aureus screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Methicillin resistant staphylococcus aureus screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Methicillin resistant staphylococcus aureus screening
CDC on Methicillin resistant staphylococcus aureus screening
Methicillin resistant staphylococcus aureus screening in the news
Blogs on Methicillin resistant staphylococcus aureus screening
Directions to Hospitals Treating Methicillin resistant staphylococcus aureus
Risk calculators and risk factors for Methicillin resistant staphylococcus aureus screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Screening

The National Committee for Clinical Laboratory Standards (NCCLS), now called the Clinical and Laboratory Standards Institute (CLSI), recommends the cefoxitin disk screen test, the latex agglutination test for PBP2a, or a plate containing 6 μg/ml of oxacillin in Mueller-Hinton agar supplemented with NaCl (4% w/v; 0.68 mol/L) as alternative methods of testing for MRSA. For methods of inoculation, see CLSI Approved Standard M100-S15.